1. Sweden Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
Medicover AB Class B

Medicover AB Class B

270.00
SEK
+4.50
(+1.69%)
5.84EPS
37.13P/E
34.95BMarket Cap
Nov 04Next Earn
Medicover AB Class B
LSE:0RPS
(London Stock Exchange)

Recent

price

270.00

P/E

ratio

37.13

div

yld

1.43%

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
EUR
2.74
3.12
5.23
4.87
5.04
6.33
7.04
9.28
10.16
11.69
13.95
15.78
16.37
Revenue per Share
0.03
0.06
0.05
0.16
0.17
0.17
0.18
0.69
0.08
0.12
0.11
0.51
0.56
Basic EPS, GAAP
-0.01
-0.02
-0.87
0.18
-0.06
-0.29
0.58
0.77
0.2
0.63
0.93
1.23
1.09
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
0.07
0.12
0.12
0.12
0.15
0.35
Dividend per Share
0.66
0.67
0.7
2.22
2.35
2.38
3.02
3.49
3.17
3.32
3.1
3.53
3.53
Book Value per Share
-0.18
-0.27
-0.43
1
0.84
-0.4
0.63
0.48
-1
-0.95
-1.28
-1.86
-1.84
Tangible Book Value per Share
133
133
95
119
133
133
142
148
149
149
150
151
151
Basic Weighted Avg Shares
365
416
497
580
672
844
998
1,377
1,510
1,746
2,092
2,378
2,473
Sales/Revenue/Turnover
4.6
5.17
4.24
4.96
5.02
5.54
6.59
11.57
3.75
3.5
4.14
6.55
7.07
Operating Margin (%)
18
18
23
26
57
74
96
111
162
183
198
215
220
Depreciation Expense
4
8
4
19
22
23
26
102
12
18
17
78
85
Net Income, GAAP
63.57
46.11
47.15
27.86
23.66
25.83
26.81
25.87
29.74
22.03
27.36
26.12
26.32
Effective Tax Rate (%)
1.18
1.8
0.86
3.22
3.32
2.66
2.59
7.39
0.78
1.01
0.8
3.26
3.42
Profit Margin (%)
-72
39
37
36
59
-66
61
227
-22
-119
-120
-211
-434
Working Capital
- -
126
195
138
223
306
318
675
838
775
981
1,095
862
LT Debt
91
93
99
300
318
360
484
562
509
528
489
545
553
Total Equity
- -
5.46
3.44
5.24
4.87
4.95
5.36
10.68
2.74
3.17
3.1
6.13
6.76
Return on Invested Capital (%)
- -
3.64
1.7
5.31
5.3
4.4
4.52
10.28
2.46
3.82
3.77
6.98
7.3
Return on Capital (%)
- -
8.44
4.73
9.62
7.32
7.14
6.74
21.09
2.38
3.63
3.47
15.54
16.5
Return on Common Equity (%)

Capital Structure

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
345
324
599
LT Borrowings
621
628
389
LT Finance Leases
474
469
473
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
151
151
152
Market Capitalization
3,074
2,599
3,156

Working Capital

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
497
512
530
Cash, Cash Equivalents & STI
88
86
93
Accounts Receivable, Net
229
360
370
Inventories
67
66
67
Total Current Liabilities
708
689
964
Payables & Accruals
- -
- -
- -
ST Debt
345
324
599
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
27.76%
2.92%
11.36%
Free Cash Flow
394.41%
52.88%
32.95%
Net Income, GAAP
94.13%
122.85%
364.07%
Sales/Revenue/Turnover
19.28%
19.36%
13.69%
Total Cash Common Dividend
- -
- -
25%

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
499
509
528
556
2,092
2025
578
597
- -
612
2,378
2026
624
640
- -
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.04
-0.03
0.06
0.11
2025
0.13
0.13
- -
0.12
0.51
2026
0.15
0.16
- -
- -
- -

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.12
- -
- -
0.12
2025
- -
0.15
- -
- -
0.15
2026
- -
0.2
- -
- -
- -
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
Medicover AB (publ) delivers comprehensive healthcare and diagnostic solutions across Europe and India, maintaining its headquarters in Stockholm, Sweden. The company operates through distinct divisions: Healthcare Services and Diagnostic Services. Its healthcare arm encompasses primary care, specialized outpatient and inpatient treatments, fertility clinics, dental facilities, hospitals, and wellness centers. Within diagnostic services, Medicover provides an extensive array of laboratory tests for human health, covering areas such as allergy and autoimmune conditions, microbiology, clinical chemistry, hematology, histopathology, molecular biology, and genetics, alongside some veterinary diagnostics. This is all supported by a wide-reaching "hub-and-spoke" laboratory network. Serving a diverse clientele including corporate entities, private individuals, and public healthcare systems, Medicover focuses on growth in Central and Eastern European markets, as well as India. Its operational footprint spans Germany, Poland, Romania, Ukraine, Bosnia-Herzegovina, Bulgaria, Croatia, Cyprus, Georgia, Greece, Moldova, North Macedonia, Turkey, Serbia, Slovenia, and India, among others. Medicover reported robust financial performance in the third quarter of 2025, with revenues climbing to €591.6 million and a positive shift in net income year-over-year. Recent strategic movements include the acquisition of SYNLAB Group’s businesses in several Central and Eastern European countries in April 2025, significantly expanding its diagnostic reach with additional laboratories and blood-drawing points. In India, Medicover Hospitals, which already operates 23 hospitals and two cancer centers, is evaluating a potential separate listing and plans further expansion with new hospital openings. The company, established in 1995, also saw a leadership transition with John Stubbington appointed as the new CEO in May 2025.